Regeneron

Company Overview

A leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases through physician-scientist leadership. Regeneron focuses on translating science into medicine repeatedly and consistently across multiple therapeutic areas. The company operates with end-to-end research and development capabilities spanning discovery through commercialization. Founded and led by physician-scientists, Regeneron has built a reputation for bringing innovative treatments to patients with serious unmet medical needs.

Headquarters and Global Presence

Regeneron is headquartered in Westchester County, New York, where it maintains its primary research and development operations. The company operates as a global biotechnology enterprise with significant commercial presence across major pharmaceutical markets. Its integrated approach combines research, manufacturing, and commercialization capabilities primarily from its New York base.

Founding and History

Regeneron was founded in 1988 by Leonard Schleifer and George Yancopoulos, both physician-scientists who continue to lead the company today. Originally focused on neurotrophic factors and their regenerative capabilities, which gave rise to the company's name, Regeneron has since expanded into cytokine and tyrosine kinase receptor research. The company has grown from its neuroscience origins into a diversified biotechnology leader with multiple approved medicines. Over 35 years of operation, Regeneron has consistently demonstrated its ability to translate scientific discoveries into commercial therapies.

Therapy Areas and Focus

Regeneron operates across multiple therapeutic areas including oncology, ophthalmology, inflammatory diseases, and rare genetic disorders. The company's immuno-oncology portfolio represents a significant focus area, leveraging immune system modulation for cancer treatment. Ophthalmology remains a core strength with established treatments for retinal diseases. Regeneron also pursues inflammatory and allergic conditions, demonstrating breadth across serious disease areas with substantial unmet medical needs.

Technology Platforms and Modalities

Regeneron's technology foundation centers on antibody discovery and development platforms that enable systematic identification of therapeutic targets. The company utilizes advanced protein engineering and mouse genetics technologies to create highly specific therapeutic antibodies. Their VelociGene platform allows for rapid generation and characterization of genetically modified mouse models for target validation. These integrated platforms support both internal discovery programs and collaborative research initiatives with external partners.

Key Pipeline and Programs

Regeneron's commercial portfolio includes Eylea for retinal diseases, Dupixent for atopic dermatitis and asthma, and Libtayo for certain cancers. The company maintains an active clinical pipeline across oncology, ophthalmology, and inflammatory diseases with multiple programs in Phase II and Phase III development. Key investigational assets include next-generation ophthalmology treatments and immuno-oncology combinations. Recent strategic initiatives include radiopharmaceutical development through collaboration with Telix Pharmaceuticals, expanding into targeted cancer radiotherapy.

Key Personnel

Leonard Schleifer serves as Board Co-Chair, President and Chief Executive Officer, having co-founded the company in 1988. George Yancopoulos is Board Co-Chair, President and Chief Scientific Officer, also a company founder and key architect of Regeneron's scientific strategy. Both leaders maintain active roles in guiding the company's research direction and strategic development as physician-scientists.

Strategic Partnerships

Regeneron maintains a collaborative approach to drug development with multiple strategic partnerships across its therapeutic areas. The company recently announced a strategic collaboration with Telix Pharmaceuticals for radiopharmaceutical development, combining Regeneron's antibody platforms with Telix's radiotherapy expertise in a 50/50 cost and profit-sharing model. Regeneron typically leverages partnerships to access complementary technologies and expand its therapeutic reach while maintaining strong internal capabilities. The company's collaboration strategy focuses on enhancing its core competencies rather than replacing them.

FAQ Section